Pexidartinib hydrochloride - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic sources for pexidartinib hydrochloride and what is the scope of freedom to operate?
Pexidartinib hydrochloride
is the generic ingredient in one branded drug marketed by Daiichi Sankyo Inc and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.Pexidartinib hydrochloride has one hundred and twenty-seven patent family members in forty-one countries.
One supplier is listed for this compound.
Summary for pexidartinib hydrochloride
International Patents: | 127 |
US Patents: | 12 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 17 |
Clinical Trials: | 17 |
Patent Applications: | 24 |
DailyMed Link: | pexidartinib hydrochloride at DailyMed |
Recent Clinical Trials for pexidartinib hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Daiichi Sankyo Co., Ltd. | Phase 2 |
Daiichi Sankyo, Inc. | Phase 4 |
Daiichi Sankyo Co., Ltd. | Phase 3 |
US Patents and Regulatory Information for pexidartinib hydrochloride
International Patents for pexidartinib hydrochloride
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2018515490 | キナーゼを調節する化合物の固体形態 | See Plans and Pricing |
Israel | 255313 | See Plans and Pricing | |
China | 110944670 | 调制激酶的化合物的制剂 (Formulations of a compound modulating kinases) | See Plans and Pricing |
Australia | 2018307910 | Formulations of a compound modulating kinases | See Plans and Pricing |
Japan | 6946194 | See Plans and Pricing | |
Hong Kong | 1248675 | 調節激酶的1H 吡咯並[2,3-B]吡啶衍生物的合成 (SYNTHESIS OF 1 H-PYRROLO[2,3-B]PYRIDIN DERIVATIVES THAT MODULATE KINASES) | See Plans and Pricing |
Japan | 6986045 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |